Avid Radiopharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Philadelphia PA United States (2005)
Status: Acquired by Eli Lilly (2010)

Organization Overview

First Clinical Trial
2007
NCT01565291
First Marketed Drug
2012
erwinia asparaginase (Erwinaze)
First NDA Approval
2012
florbetapir (Amyvid)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Avid Radiopharmaceuticals | Avid Radiopharmaceuticals, Inc. | AVID RADIOPHARMS INC